Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.8% |
| LEE, CHIHYI NMN | 1 | 32.9% | +58.5% |
| MCINTOSH III, TRAVISS C | 1 | 73.2% | +14.0% |
| ALBERTALLI, BRIAN LOUIS | 1 | 81.9% | +16.6% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.4% | +40.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17927234 | INTELLIGENT TRANSCRIPTION AND BIOMARKER ANALYSIS | ALBERTALLI, BRIAN LOUIS | 5d overdue |
| 18267827 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | MCINTOSH III, TRAVISS C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17927234 | INTELLIGENT TRANSCRIPTION AND BIOMARKER ANALYSIS | ALBERTALLI, BRIAN LOUIS | 5d overdue |
| 18703950 | TREATMENT OF TREATMENT RESISTANT DEPRESSION WITH PSILOCYBIN | KIFLE, BRUCK | — |
| 18433051 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | ANDERSON, REBECCA L | — |
| 18420562 | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES | LEE, CHIHYI NMN | — |
| 18267827 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | MCINTOSH III, TRAVISS C | — |
| 18021243 | NOVEL PSILOCIN DERIVATIVES HAVING PRODRUG PROPERTIES | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1628 | 1 |
| 1693 | 1 |
| 2656 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18703950 | TREATMENT OF TREATMENT RESISTANT DEPRESSION WITH PSILOCYBIN | KIFLE, BRUCK | — | §103 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18433051 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | ANDERSON, REBECCA L | 1626 | DP | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18420562 | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES | LEE, CHIHYI NMN | 1628 | §103§112DPOther | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18267827 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | MCINTOSH III, TRAVISS C | 1693 | §102§103§112 | Final Rejection | — | Pending | Jun 16, 2023 |
| 17927234 | INTELLIGENT TRANSCRIPTION AND BIOMARKER ANALYSIS | ALBERTALLI, BRIAN LOUIS | 2656 | §102§103 | Non-Final OA | 5d overdue | Pending | Jun 01, 2023 |
| 18021243 | NOVEL PSILOCIN DERIVATIVES HAVING PRODRUG PROPERTIES | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §102§103DPOther | Final Rejection | — | Pending | Feb 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial